Prime Vector Technologies

exist’s research transfer program played a crucial role in the journey from research to company founding. As CEO Ralf Amann explains, the biggest challenge in vaccine and therapeutic research is that there are numerous development and validation steps between a promising scientific idea and its eventual application in humans. This phase in particular is associated with high costs, long development times, and considerable risk. The exist research transfer program gave the team the necessary freedom to further develop the technology in a targeted manner while simultaneously laying the groundwork for the company. In addition, Amann highlights the added value of the exist network. The exchange of ideas and early networking with potential partners provided the team with important impetus and supported the company’s growth. It was precisely this combination of financial support and personal networking that helped Prime Vector Technologies successfully make the transition from research to the market.

Today, Prime Vector Technologies continues to advance its platform technology and is working with partners on new vaccine and immunotherapy approaches. Among its most important milestones is its collaboration with Boehringer Ingelheim, through which the company is further advancing its technology toward clinical application. In doing so, the company is steadfastly pursuing its path and driving the development of innovative therapies for human and veterinary medicine. At the same time, Ralf Amann is looking to the future: He would particularly like to see more investment in medical research so that promising scientific innovations can find their way into practical application more quickly. In his view, funding programs such as the exist Research Transfer program make an important contribution to translating research findings into successful companies and new medical solutions.